Adaptive Biotechnologies (ADPT) CSO sells 10,000 shares at $16.44

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins sold 10,000 shares of common stock on January 6, 2026. The sale was reported at a weighted average price of $16.44 per share. According to the disclosure, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Robins adopted on August 11, 2025. After this sale, he beneficially owned 1,222,312 shares of Adaptive Biotechnologies common stock.

Insider Trade Summary

Net Seller: 10,000 shares ($164,400)

Net Sell 1 txn

Insider ROBINS HARLAN S

Role Chief Scientific Officer

Sold 10,000 shs ($164K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$16.44	$164K

Holdings After Transaction: Common Stock — 1,222,312 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBINS HARLAN S

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		10,000	D	$16.44(2)	1,222,312	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

	/s/ Harlan S. Robins by Kyle Piskel, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADPT report for Harlan S. Robins?

Adaptive Biotechnologies Corp (ADPT) reported that Chief Scientific Officer Harlan S. Robins sold 10,000 shares of common stock on January 6, 2026.

At what price were the ADPT shares sold in this Form 4 filing?

The reported sale price was a weighted average of $16.44 per share, with individual trades executed between $16.05 and $16.78 per share.

How many ADPT shares does Harlan S. Robins own after this transaction?

Following the reported sale, Harlan S. Robins beneficially owned 1,222,312 shares of Adaptive Biotechnologies common stock.

Was the ADPT insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected under a Rule 10b5-1 trading plan adopted by Harlan S. Robins on August 11, 2025.

What role does Harlan S. Robins hold at Adaptive Biotechnologies Corp (ADPT)?

Harlan S. Robins is identified as an officer of the company, serving as Chief Scientific Officer.

Is the reported ADPT insider transaction direct or indirect ownership?

The Form 4 indicates that the transaction involved direct (D) ownership of Adaptive Biotechnologies common stock by Harlan S. Robins.